";s:4:"text";s:5409:" Committee for Proprietary Medicinal Products.
Australian Government Department of Health and Ageing. We collected solicited reports of local and systemic adverse events, using a 7-day diary card.
Flu VE Network have been published previously (3). From Clinical Research and Development, CSL, Parkville, VIC, Australia. Methods used by the U.S.
The immunogenicity of the H1N1 vaccine was evaluated with the use of hemagglutination-inhibition and microneutralization assays with methods that have been described previously11,12 (for details, see the Supplementary Appendix, available with the full text of this article at NEJM.org). For children aged 6 months–17 years, overall vaccine effectiveness was 61% (44%–73%). Stopping rules were not triggered, and there were no withdrawals because of adverse events. Rowe T, Abernathy RA, Hu-Primmer J, et al. Persons aged ≥6 months who have not yet been vaccinated this season should be vaccinated. Any adverse events of special interest or serious adverse event was to be reported within 24 hours. ), 3. Epub 2017 Oct 23.
Geneva: World Health Organization, 2009. I-007-05.) An influenza-like illness was defined as an oral temperature of more than 38°C (100.4°F) or a history of fever or chills and at least one influenza-like symptom. A preliminary version of this article (10.1056/NEJMoa0907413) was published on September 10, 2009, at NEJM.org. | Each dose was administered intramuscularly into the deltoid muscle. All solicited local adverse events were considered to be related to the H1N1 vaccine, whereas the investigator assessed the causality of solicited systemic and unsolicited adverse events.
The daggers indicate statistically significant differences in titer. URL addresses listed in MMWR were current as of
Health and Human Services. Demographic Characteristics of the Subjects. DOI: http://dx.doi.org/10.15585/mmwr.mm6806a2external icon. Participants (including children aged <9 years, who require 2 vaccine doses during their first vaccination season) were considered vaccinated if they received ≥1 dose of any seasonal influenza vaccine ≥14 days before illness onset, according to medical records and registries (at the Wisconsin site); medical records and self-report (at the Pennsylvania, Texas, and Washington sites); or self-report only (at the Michigan site). Shown are local adverse events associated with the H1N1 vaccine after the first dose (Panel A) and after the second dose (Panel B), as well as systemic adverse events (Panels C and D, respectively). 2013 Dec;7 Suppl 4(Suppl 4):2-9. doi: 10.1111/irv.12199. ), 17. The coprimary immunogenicity end points were the proportion of subjects with antibody titers of 1:40 or more on hemagglutination-inhibition assay, the proportion of subjects with either seroconversion or a significant increase in antibody titer, and the factor increase in the geometric mean titer. Influenza activity remains elevated in the United States (4). Blanton L, Dugan VG, Elal AIA, et al.
Unsolicited reports of adverse events were collected in a 21-day diary card. A safe and effective vaccine is needed. Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM. Kuehn BM. The majority of events (64.7%) were mild in intensity. We performed an additional analysis examining the effect of baseline serostatus on the immune response to H1N1 vaccination.
Hancock K, Veguilla V, Lu X, et al. All authors report being employees of CSL, and Dr. Greenberg, Dr. Lai, Dr. Hartel, Dr. Gittleson, Ms. Bennet, Ms. Dawson, Dr. Washington, and Dr. Basser report having an equity interest in the company. The purpose of this study was to evaluate the immunogenicity and safety of two different doses of the H1N1 vaccine in healthy adults between the ages of 18 and 64 years in a two-dose regimen. N Engl J Med 2009;361:279-285, 24. (Accessed November 30, 2009, at http://www.emea.europa.eu/pdfs/human/bwp/021496en.pdf. The results for NTX have been staggered next to T01 for better visualization. June 2009.
This interim estimate also is lower than the recently reported interim estimates of 72% effectiveness against A(H1N1)pdm09 in Canada during the 2018–19 season (6) and 78% against A(H1N1)pdm09 in Australia during the 2018 Southern Hemisphere influenza season (7).
Neuzil KM, Jackson LA, Nelson J, et al.
Summary of available candidate vaccine viruses for development of pandemic (H1N1) 2009 virus vaccines. London: European Medicines Agency, 1996. For this reason, the type of vaccine received by participants (e.g., egg-based, cell culture–based, or recombinant antigen) is not available at this time, although this information will be updated at the end of the season. Rolfes MA, Flannery B, Chung J, et al.
Persons identifying as Hispanic might have been of any race. Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
N Engl J Med 2017;377:534–43. The primary and secondary end-point analyses were descriptive and consisted of an assessment of the lower confidence bounds of each end point for each study group.